Update (June 12, 2026): Grapiprant vs. Meloxicam for Postoperative Joint Pain After TPLO

TL;DR

A randomized, double-blinded trial found that grapiprant provided superior pain interference and severity scores at 3 and 10 days post-TPLO compared with meloxicam, with better owner-assessed quality of life and veterinarian-assessed orthopedic recovery at 15 days.

What just dropped

• Cassemiche A et al. [via BSAVA pain management article, September 2024] https://www.bsava.com/article/whats-new-in-pain-management-and-analgesic-research/ — randomized, double-blinded, prospective clinical trial, 48 client-owned dogs with cranial cruciate ligament disease undergoing tibial plateau leveling osteotomy (TPLO). All dogs received subcutaneous meloxicam at the label dose on the day of surgery; from the following day, they were randomized to oral grapiprant at the label dose once daily or oral meloxicam at the maintenance dose once daily for 14 days. Grapiprant-treated dogs had lower pain interference scores at day 3 and day 10. Pain severity scores were lower in the grapiprant group at day 3. Owner-assessed overall quality of life and veterinarian-assessed orthopedic recovery were both superior in the grapiprant group at 15 days.
• Enomoto M et al. (2024, Front Vet Sci 11:1461628) https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1461628/full — parallel multimodal grapiprant data: in 48 young dogs with chronic OA (not post-surgical), the same grapiprant label-dose regimen delivered clinically meaningful improvements in objective gait measures and owner-reported pain scores over 4 months, supporting the drug's broader analgesic profile.

Context

The Cassemiche study is the first double-blinded RCT comparing grapiprant with an NSAID specifically in the postoperative joint pain setting in dogs. Previous evidence for grapiprant came primarily from chronic OA field studies. The TPLO model represents acute-on-chronic joint pain with a defined surgical endpoint, making the findings particularly applicable to referral orthopedic practice.

Both drugs were given orally after an initial standard perioperative NSAID dose, reflecting a clinically common protocol where surgeons want early analgesia and a subsequent oral transition. The grapiprant advantage in pain interference scores was maintained from day 3 through day 10, suggesting a benefit duration beyond the acute surgical period.

What this changes in Grapiprant (Galliprant) for Canine Osteoarthritis Pain (https://www.thevoyage.ai/forvets/knowledge/grapiprant-canine-osteoarthritis-pain)

The existing evergreen covers grapiprant's chronic OA evidence but not the postoperative setting. This RCT adds a new clinical scenario where grapiprant is at least equivalent to — and in several measured outcomes superior to — standard meloxicam dosing. Clinicians managing post-TPLO analgesia may consider this data when choosing between EP4-pathway inhibition and COX inhibition for the transitional oral phase.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-12-grapiprant-tplo-postop-pain

References

1. Cassemiche A et al. Comparison of grapiprant and meloxicam for management of postoperative joint pain in dogs: A randomized, double-blinded, prospective clinical trial. J Vet Intern Med. 2024;38(4):2324-2332. [via BSAVA] https://www.bsava.com/article/whats-new-in-pain-management-and-analgesic-research/
2. Enomoto M et al. Response to treatment with grapiprant as part of a standard multimodal regimen in young dogs with appendicular joint osteoarthritis associated pain. Front Vet Sci. 2024;11:1461628. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1461628/full

Changelog

• 2026-06-12: First published.

Related reads

• Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence